Tag: BioSig

BioSig Conducts First Patient Cases with PURE EP(tm) System at Memorial Hospital of South Bend, Indiana

PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation. Westport, CT, Jan. 12, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an […]

BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota

NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover […]

BioSig Achieves First Commercial Sale of Three PURE EP Systems

Sale Marks Milestone for Company’s Commercial expansion at leading Center of Excellence Westport, CT, Dec. 11, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of […]

BioSig Announces Completion of PURE EP™ System Installation at New Medical Center

First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center Westport, CT, Oct. 29, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the […]

BioSig Issues October 2020 Shareholder Update Letter

Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) — Company’s PURE EP™ System’s data-driven commercialization is gaining acceptance through new evaluative installations at medical centers of excellence The strongest cash balance in its history positions the Company well to execute on its strategic goals. BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or […]

BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems. Westport, CT, Sept. 15, 2020 (GLOBE NEWSWIRE) […]

ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board

Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) — Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of Fame ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), […]

BioSig Installs PURE EP(tm) System at Massachusetts General Hospital

Patient cases are set to commence in August Westport, CT, Aug. 04, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac […]

BioSig Awarded CAGE Code by the Systems for Award Management (SAM)

Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government Westport, CT, Aug. 03, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal […]

ViralClear Announces Formation of Its Scientific Advisory Board

Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) — BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory Board ViralClear Pharmaceuticals is Currently in Phase II Trials with Its Lead Asset Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) […]